Drugs / Autologous peripheral blood-derived tolerogenic dendritic cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05554484 | Jun 2021 → Jul 2023 | myocardial infarction | The Catholic University of Korea | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous peripheral blood-derived tolerogenic dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05554484 ↗ |
| Known as | AMI-DC | “AMI-DC, autologous dendritic cell product” NCT05554484 ↗ |
| Modality | Cell therapy | “autologous dendritic cell product” NCT05554484 ↗ |
| Route | Subcutaneous | “cells are administered subcutaneously” NCT05554484 ↗ |